MB-1 for Obesity

MM
Overseen ByMarc Moulin, PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines how a new treatment, MB-1, affects weight and health in overweight and obese adults. MB-1 contains natural ingredients such as African mango seed and green tea extract. Researchers aim to determine if MB-1 can reduce body weight and body mass index (BMI) compared to a placebo. Ideal participants are adults with a BMI between 25 and 34.9 and a waist size over 37 inches for men or 31.5 inches for women. Participants must maintain their lifestyle and complete various assessments during the trial. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research on natural weight management solutions.

Is there any evidence suggesting that MB-1 is likely to be safe for humans?

Research has shown that the individual ingredients in MB-1 are generally safe. African mango seed and Cissus leaf extract, for instance, are often used in weight loss products and are usually well-tolerated. Grains of Paradise and Green tea extract are also common and have a good safety record.

The combination of these ingredients in MB-1 aims to boost metabolism, reduce cravings, and increase energy levels. Although specific safety data on MB-1 as a complete formula is not yet available, its ingredients are widely used and considered safe by many. However, as MB-1 is a supplement, it is not regulated as strictly as prescription drugs. This means that while the ingredients have been used safely in other products, detailed safety information on MB-1 as a whole is still being collected.

Consulting a healthcare provider before joining a trial is always advisable, especially if there are any safety concerns.12345

Why are researchers excited about this trial's treatment for obesity?

Researchers are excited about MB-1 for obesity because it combines natural ingredients that may offer a new approach to weight management. Unlike existing medications that often focus on suppressing appetite or inhibiting fat absorption, MB-1 targets metabolic pathways using African mango seed, Cissus leaf extract, and Grains of Paradise. These components are believed to help boost metabolism and improve gut health, potentially leading to more effective weight loss. Additionally, the inclusion of Bifidobacterium Lactis B420 suggests a unique focus on gut microbiota balance, which is an emerging area of interest in obesity treatment.

What evidence suggests that MB-1 might be an effective treatment for obesity?

Research shows that some ingredients in MB-1, a treatment in this trial, such as African mango seed and green tea extract, may aid in weight loss. African mango seed might reduce body fat and improve cholesterol levels. Green tea extract, containing caffeine, could boost metabolism and help burn fat. Cissus quadrangularis is another ingredient that may support weight loss and enhance metabolism. Bifidobacterium lactis, a probiotic, might aid weight management by improving gut health. Although these ingredients have shown promise individually, limited research exists on the effectiveness of their combination in MB-1 for reducing weight or BMI in overweight and obese adults. Participants in this trial will receive either MB-1 or a placebo to assess its effectiveness.678910

Who Is on the Research Team?

DC

David Crowley, MD

Principal Investigator

KGK Science Inc.

Are You a Good Fit for This Trial?

This trial is for overweight and obese adults interested in improving their metabolic health. Participants should be willing to take MB-1 or a placebo, undergo body measurements, blood pressure and heart rate checks, answer questionnaires about hunger/fullness, and have a DEXA scan.

Inclusion Criteria

Stable body weight defined as a <5% change in body weight in the three months prior to baseline
Healthy as determined by medical history as assessed by Qualified Investigator (QI)
My waist is over 94 cm if I am a man, or over 80 cm if I am a woman.
See 6 more

Exclusion Criteria

My blood pressure is stable with medication for the last 3 months.
My only cancer was skin basal cell carcinoma, fully removed, or any cancer I had is in remission for over 5 years.
Individuals with an autoimmune disease or are immune compromised as assessed by the QI
See 26 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive MB-1 or placebo and are assessed for various health metrics

12 weeks
Weekly assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • MB-1

Trial Overview

The study tests the safety and effectiveness of MB-1 compared to a placebo on weight management over 84 days. It measures changes in body weight, BMI, appetite control, and overall metabolic health.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: PlaceboExperimental Treatment1 Intervention
Group II: MB-1Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Arrae

Lead Sponsor

Trials
1
Recruited
40+

KGK Science Inc.

Industry Sponsor

Trials
82
Recruited
6,400+

Najla Guthrie

KGK Science Inc.

Chief Executive Officer since 1997

Research career at the Centre for Human Nutrition, University of Western Ontario

Dr. Bibiane Zakaria

KGK Science Inc.

Chief Medical Officer since 2023

MD from an unspecified institution

Citations

Real‐world evidence on the utilization, clinical and ... - PMC

In individuals without T2D, weight loss was 6.9% for semaglutide, 6.6% for liraglutide and 3.1% for dulaglutide. A newer large real‐world comparative cohort ...

Time-Restricted Feeding Reduces Body Mass Index ...

Emerging evidence demonstrates that TRF influences metabolic and immune pathways independent of weight loss by modulating the intestinal ...

Once-Weekly Semaglutide in Adults with Overweight or ...

In the semaglutide group, approximately 70% of participants achieved a weight loss of at least 10%, and approximately 50% achieved a weight loss ...

One-Year Weight Reduction With Semaglutide or ...

However, 61.0% of the patients who received semaglutide for obesity and with persistent coverage at 1 year achieved 10% or greater weight loss, ...

A Clinical Trial to Investigate the Safety and Efficacy of MB ...

The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults.

A Clinical Trial to Investigate the Safety and Efficacy of MB ...

The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults.

MB-1 (Metabolic Burn)

If your BMI is less than 25, MB-1 is an excellent choice for reducing cravings, increasing energy levels, boosting daily calorie burn, and improving overall ...

The Complete Guide to MB-1: Everything You Need To Know

MB-1 works to optimize your metabolism for significant improvements in energy levels, body composition, satiety, & overall metabolic health. How ...

Arrae is yet another supplement company using the Appeal ...

GLP-1 agonists have been used since 2005 and have a great safety record. As far as supplements, they're barely regulated by the FDA, who steps ...

MB-1 Impact on Metabolic Health in Overweight and Obese ...

This clinical trial focuses on exploring the safety and efficacy of a treatment called MB-1 in improving metabolic health among adults who ...